Figure 1. Identification of Completed Pan-Canadian Oncology Drug Review (pCODR) Submissions of Drugs for Solid Tumor Indications Between July 2011 and February 2020.

Of the 9 resubmissions, 7 were previously submitted and received a negative reimbursement recommendation and 2 were withdrawn from consideration before the final reimbursement recommendation was delivered.